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Background: The recent exponential growth of Digital Health (DH) in the healthcare
system provides a crucial transformation in healthcare, answering to alarming threats
related to the increasing number of Chronic Neurological Diseases (CNDs). New
long-term integrated DH-care approaches, including rehabilitation, are warranted to
address these concerns.
Methods: The Human Empowerment Aging and Disability (HEAD) rehabilitation
program, a new long-term integrated care including DH-care system, was evaluated
in terms of efficiency and patient-reported outcome measures (PROMs) in 107 CND
patients (30 with Parkinson’s Disease, PD; 32 with Multiple Sclerosis, MS; 45 with
stroke in chronic stage). All participants followed 1-month of HEAD rehabilitation in
clinic (ClinicHEAD: 12 sessions, 3/week), then 1:3 patient was consecutively allocated
to 3-months telerehabilitation at home (HomeHEAD: 60 sessions, 5/week). Efficiency
(i.e., adherence, usability, and acceptability) and PROMs (i.e., perceived functioning in
real-world) were analyzed.
Results: The rate of adherence to HEAD treatment in clinic (≥90%) and at home
(77%) was high. Usability of HEAD system was judged as good (System Usability Scale,
median 70.00) in clinic and even more at home (median 80.00). Similarly, administering
the Technology Acceptance Model 3 questionnaire we found high scores both in clinic/at
home (Usefulness, mean 5.39± 1.41 SD/mean 5.33± 1.29 SD; Ease of use, mean 5.55
± 1.05 SD/ mean 5.45 ± 1.17 SD, External Control, mean 4.94 ± 1.17 SD/mean 5.07
± 1.01 SD, Relevance, mean 5.68 ± 1.29 SD/mean 5.70 ± 1.13 SD and Enjoyment,
mean 5.70 ± 1.40 SD/mean 6.01 ± 1.08 SD). After ClinicHEAD, participation and
autonomy in daily routine was maintained or even ameliorated (PD and stroke > MS).
Whereas, increased functionality and participation in the MS group was found only after
HomeHEAD intervention.
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Discussion: Our results suggest that a tele-health-based approach is both feasible
and efficient in providing rehabilitation care to CNDs from clinic to home. Increasing and
maintaining participation as well as autonomy in daily routine are promising findings that
open up scenarios for the continuity of care at home through DH-care for CNDs.
Keywords: rehabilitation, technology, telerehabilitation, nervous system diseases, multiple sclerosis, Parkinson’s
disease, stroke
INTRODUCTION
Parkinson Disease (PD), Multiple Sclerosis (MS), and Stroke are
the more frequent chronic Neurological Diseases (CNDs) that
can lead to significant motor and cognitive disability: worldwide
data report 2.5 million people with MS (1), 7.9 to 19 individuals
with PD per 100,000 person-year (2) and 5.5 million deaths due
to stroke in 2016 (3). In recent years, newmodels of digital health
(DH) enabling continuity of care are increasingly explored as new
solutions to the long-term patient maintenance. Also, growing
effort has been spent in the development of technology-enabled
treatments, able to be carried out outside clinic setting, with
promising results (4–14). Especially, telerehabilitation aids in
decreasing socioeconomic costs related to these pathologies and
their weight on the healthcare system (15–17). Also, technology-
enabled rehabilitation at home allows people with chronic
diseases to combine pathology management with their everyday
social life (5).
To ensure effectiveness of tele-treatment, a continuous double
loop communication between home and clinic environment is
needed: in this sense, digital health care platforms constitute
the central hub through which health professionals can
monitor patient performance at home (18) and consequently
modify treatment during the whole period of telerehabilitation.
Frequency of rehabilitation and duration of treatment are
important parameters that should not be overlooked. In fact,
there are health care guidelines for clinical practitioners that
detail the frequency and duration of rehabilitation activities
specifically for different pathologies, such as MS, PD and stroke
(19). For example, strength training, reported as efficacious for
MS, PD and stroke patients (20–22) should be performed 2–3
days per week to reach benefits on daily living with a duration
per session ranging between 10 and 40minutes. However, little
is known regarding frequency and dose treatment guidelines for
treatments administered in a home-based setting.
Unfortunately, adherence to home rehabilitation protocols,
including telerehabilitation, is a concern (23). People with
neurological disorders that could benefit from rehabilitation
often do not adhere to a prescribed protocol once they are in their
home environment. This could provide serious consequences,
such as loss of functioning, pain, muscle wasting etc., that are
risks deriving from a lack of rehabilitation not only in an acute
condition, but also in a chronic phase. Few recent studies have
investigated the factors affecting adherence in order to predict
and enhance adherence to telerehabilitation. An interesting work
created a quantitative adherence prediction model based on
baseline patients’ characteristics by individualizing an important
predictive role of education, satisfaction about the treatment
and psychological profile (24). Another contribution investigated
variation of adherence to treatment comparing different modes
of cycling treatment administration, such as active or passive
exercises, reporting more satisfying adherence to the passive
mode of exercises (25). These contributions demonstrated a
pivotal interest on the topic.
Another aspect to be considered regarding new DH
approaches is the active role of the patient that is empowered
and engaged in own care management, with consequences also
on perceived care outcome. In particular, an “e-patients” term has
been coined to highlight patients involved in decision-making
and management of their own care (26). In fact, patient-reported
outcome measures (PROMs) are increasingly used as real-world
functioning measures that incorporate self-defined assessments
of personal well-being during the management of care (27).
Recent clinical practice health guidelines promote the integration
of these latter measures into long-term care of patients (28).
The present study aims to report results on efficiencymeasures
and PROMs of the Human Empowerment Aging and Disability
program (HEAD), a DH-telerehabilitation system for people with
chronic neurological diseases. In particular, we tested HEAD
treatment during 1-month of rehabilitation program in clinic and
during 3-months of HEAD telerehabilitation at home, comparing
patients performances for PD, MS, and chronic stroke.
MATERIALS AND METHODS
Participants
The study was carried out in two steps: ClinicHEAD and
HomeHEAD. In the ClinicHEAD (first step) subjects with
PD, MS, and chronic stroke (N = 107) were consecutively
recruited. They were identified by the neurologists of the clinics
from people that periodically receive neurological follow-up
(outpatients) from the respective centers: Valduce Hospital Villa
Beretta Rehabilitation Center in Lecco (n = 34; 17 stroke, 7 PD,
10MS), IRCCSDon Carlo Gnocchi Foundation inMilan (n= 43,
12 stroke, 10 PD, 21MS) and District Clinic San Camillo in Turin
(n= 30, 16 stroke, 13 PD, 1 MS).
Inclusion criteria for enrollment were: [a] age range 18–80; [b]
diagnosis of PD in stable treatment for at least 3 years and with a
Hoehn and Yahr score≤ 2 (29), diagnosis of MS without relapses
in the last 3-months and with an Expanded Disability Status Scale
[EDSS (30)] score ≤ 5.5, diagnosis of stroke in chronic phase, at
least 6-months after the acute event.
Exclusion criteria for recruitment were the following: [a]
Mini Mental State Examination (31) score < 20; [b] presence
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of disabling pain; [c] upper limb limited passive range of
motion; [d] epilepsy; [e] severe deficit of visual acuity and
auditory perception; [f] severe deficit in communication and
severe dysmetry.
After enrollment and baseline assessment, they
were consecutively assigned into the Clinic and Home
HEAD programs.
All participants provided written and informed consent to
take part in the study.
The HEAD Program
The HEAD rehabilitation was conceived as a multidimensional
program for the continuity of care at home for patients
with chronic neurological diseases. It aimed to enhance
motor and cognitive abilities such as balance, lower and
upper body endurance, strength and speed, memory, executive
functions, language and dual-tasking activities, in order to
improve patient’s everyday functional skills. Procedure and
contents of each rehabilitative activity was defined by a health
professionals’ team including neurologists, physiotherapists and
neuropsychologists. Table 1 describes all activities included in
HEAD rehabilitation program.
The HEAD virtual platform represented the hub for
communication between the clinic and the patient’s home,
allowing rehabilitation activities to be administered through a
gaming setting in order to work on goal-directed movements in
a virtual reality (VR) scenario. This platform was designed as a
bridge between clinic and patient’s home setting, making a double
loop feedback possible between the two environments. Before
every rehabilitation session, physiotherapists and psychologists
defined the contents of the session, in the sense of type of
activities, repetitions and level of difficulty through the HEAD
virtual platform. In this manner, although HEAD technology
allowed the same setting for each patient, contents of the
rehabilitation program were tailored and personalized according
to the different needs related to the pathology of the patient
and the level of disability. Patients accessed the platform with
their own credentials to start each telerehabilitation session
and, health professionals were able to tailor rehabilitation
along the whole period of treatment by remotely checking the
quality of the gaming performance of the patient reported in
the platform.
To run the HEAD program, a PC, internet connection and
motor capture devices, such as Kinect (Microsoft, WA, USA) and
Leap Motion (Leap Motion Inc., CA, USA), were needed.
The rehabilitation activity was embedded in short video
clips. Each video clip lasted from 2 to 9minutes, and was
interrupted between 2 to 6 times on the basis of repetitions
of the rehabilitation activity. In general, video clips had
three main purposes: as motivating breaks that inter-cut
the rehabilitative activities, providing emotional and cognitive
stimuli regarding the rehabilitative activities, or awarding the
participant at the end of the exercise. Many of the motor
and cognitive exercises were directly related to the video.
Thus, participants had to erase an image just seen, by
means of large movements of the arms in order to continue
watching the clip. Alternatively, participants were asked to
order the sequences of the film clip just seen, or had to
answer questions about the content of the film clip. Patients
thus actively controlled their viewing of the movie clips and
their progression.
Each activity ended with a feedback of the results, according
to an algorithm based on the percentage of completion, number
of errors and duration of the performance. The scoring was
illustrated by stars, with a minimum of 1 to a maximum of 5 stars
being awarded.
During the month of treatment in clinic, the HEAD program
was supervised by physiotherapists and neuropsychologists and
was administered through 45min sessions 3 times per week.
Once at home, the HEAD program was carried out five
consecutive days per week, 30–45min each session.
Each participant accessed the HEAD portal through his
personal credentials to perform his own individual daily program
consisting of 3–6 neuromotor activities according to his needs.
The participants were free to choose the time of day andweekdays
in which to carry out the activities. Finally, participants had
the opportunity of calling the Help Desk Service or therapists
for technical problems or related issues. A phone call by
therapists to participants was planned once a week to check for
patient compliance.
Measures
All patients recruited were administered a rehabilitation with VR
technology for 1-month in clinic (Time 1: ClinicHEAD). After
rehabilitation in clinic, patients were consecutively allocated
to HEAD telerehabilitation at home for 3-months (Time 2:
HomeHEAD) with a ratio of 1:3. This ratio was due to the limited
availability of the HEAD technological kits. For this reason, one
patient each three was allocated to continue treatment for 3-
months at home. In the second step of the study the participants
not allocated to the HomeHEAD group were asked to not
participate in physical activities different from those that they
would usually do during the protocol duration (control group).
Subsequent contributions will report efficacy of HEAD treatment
based on outcome measures in each CND included in the study.
Efficiency and Patient-Reported Outcome measures were
collected after ClinicHEAD rehabilitation (Time 1) and after
3-months of HomeHEAD treatment by clinicians blind to the
treatment allocation (Time 2).
Part of data were obtained through questionnaires
administered by a psychologist, while remaining data were
extracted from the HEAD platform.
The present work, registered as Clinical Trial ID:
NCT03025126, provides preliminary data on efficiency of
the HEAD protocol.
Baseline Assessment
Patients recruited were screened with:
(1) Montreal Cognitive Assessment [MoCA (32)] as a measure
of global cognitive functioning. Conti’s correction was
adopted to transform scores on the basis of age and
years of education of people. This tool allowed a brief
screening of cognitive level evaluating different domains:
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TABLE 1 | List and brief description of HEAD activities.
Activities Description
UPPER LIMBS WARMING-OUT
“Delete and Go” Movie stops and subject has to perform movements of arms detected by Kinect or Leap Motion Controller (LMC) in order
to delete the movie screenshot that appears in the screen. When the 80% of the screenshot has been deleted the movie
continues
“Unveil and Go” Movie stops and subject has to perform movements of arms detected by Kinect or LMC in order to unveil the screenshot of
the movie that appears covered on the screen. When the 80% of the screenshot has been unveiled the movie continues
“Swim and Go” Movie stops and subject is required to perform a certain numbers of strokes detected by Kinect or LMC to continue the
vision of the movie
LOWER LIMBS WARMING-OUT
“Up and Go” Movie stops and subject is asked to perform up-the-stairs movements detected by Kinect to climb virtual stairs in order to
reach the movie screenshot that appears at the end of the stairs and let video continue
“Goal and Go” Movie stops and subject has to perform a hit-the-ball movement detected by Kinect: each correct movement corresponds
to a percentage of zooming of the screenshot of the movie. The maximum zoom of the screenshot let movie continue
UPPER LIMBS PRECISE MOVEMENT
“Turn pages and watch” Movie stops and a book with figures related to the video appears. Subject has to perform turn-pages movements detected
by LMC to let movie continue
“Grasp and Move” Movie stops and different images presented in the video appear on the screen. Subject has to grasp and move them in a
box through hand movement detected by Kinect or LMC to let video continue
“Pinch and Take” Movie stops and different images presented in the video appear on the screen. Subject has to grasp and move them in a
box through pinch movement detected by LMC to let video continue
LOWER LIMBS PRECISE MOVEMENT
“Dribble and watch” Movie stops and subject has to juggle a ball by performing dribble-ball movements detected by Kinect sensor to let video
continue
“March and Go” Movie stops and subject has to perform march movements detected by Kinect in order to get nearer the screenshot of the
movie, that appears far, to let video continue
TORSO MOVEMENT
“Play and watch” Movie stops and subject has to play drums by managing the movement of the chopstick through torso movements
detected by Kinect to let video continue
EXECUTIVE FUNCTION
“Maze” After watching video, subject has to perform harm and torso movements detected by Kinect to guide a ball in a maze in
order to reach the exit which reports the right category of the video
“Shaky Trunk” After watching video, several words, both related to the movie and not related, appear on the screen. Subject has to select
only the words related to the video by a grasp movement of the hand detected by Kinect. Then, different trunks on which is
placed a ball appear. Subject has to manage the direction of the ball through torso movements detected by Kinect in order
to let the ball fall in the box of the same color
“Puzzle” Movie stops and subject has to complete a puzzle depicting a screenshot of the movie
MEMORY
“In the box” After watching video, subject is required to perform torso or hand movements detected by Kinect in order to manage the
direction of a box while images related and not related to the movie fall up to down. Subject has to catch only images
related to the movie
“Reorder and win” After watching video, subject has to order a set of screenshots following the sequential order of video events through arm
movements detected by LMC
LANGUAGE
“Quiz: grasp the answer” After watching video, subject has to solve a quiz by choosing the right answer regarding video content through hand
movements detected by LMC
LEISURE ACTIVITIES
“Shaving”/ “Making-up”/“Shampooing” Subject has to reorder actions required for shaving/making-up/shampooing in sequence. Then, different objects appear on
the screen and subject is required to grasp a certain object related with this activity. Finally, a photo of a man appears on
the screen and subject has to imitate movements related to shaving/making-up /shampooing on the image by hand
movements detected by LMC. After activity, movie start as a reward
DUAL TASK
“Pair symbols with similarity” Different images appear on the screen. Subject has to pair equal images with ratio 1:1 or 1:2 or 1:3 and move them in a box
by paying attention to do not touch different images through hand movements detected by LMC. After activity, movie start
as a reward
“Pair number and object” Subject has to memorize an association between number and object and then pair the right number with the right object
through hand movements detected by LMC. After activity, movie start as a reward
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attention, executive functions, memory, language, visual-
spatial abilities, abstraction, calculation, and orientation.
Score range is 0–30, with a maximum score of 30.
(2) 2 Minute Walk Test [2MWT (33)] for a quantitative analysis
of gait endurance. Participants were instructed to walk as
far as possible over 2minutes and the distance covered
was collected.
(3) 10 Meter Walk Test [10MWT (34)] to measure gait speed.
Participants were required to walk 10 meters while time was
measured. The score was obtained by dividing the distance
by the time spent to cover it.
Output Measures
System Usability Scale [Brooke (35)] was administered for a
measure of perceived easiness of use of the HEAD system. This is
a 10-item, 5 point Likert scale (1= strongly disagree, 5= strongly
agree). Scoring instructions of Brooke (35) were considered. The
final score ranges from 10 to 100. A cut-off score, indicating a
satisfying level technological system’s usability, is 68. Learnability
and usability sub-scores were also obtained in accordance to
Lewis and Sauro’s indications (36, 37).
Adherence to treatment in clinic and at home was calculated
by extracting the following indexes from output of the platform:
percentage of total sessions performed, mean number of activities
performed per session, mean duration of activities performed
per session. We analyzed the same indexes singularly per each
week of telerehabilitation at home. Additionally, we analyzed
the number of sessions per week performed considering 3
session/week as the recommended frequency of rehabilitation,
following Kim’s et al. (19) indications. We considered as drop-
out participants who followed<50% of treatment period in clinic
(<2 weeks of treatment) and at home (<6 weeks of treatment).
Technology Acceptance Model-3 (38) was utilized in order to
deepen patients’ beliefs related to their inclination to experience
the HEAD system. This scale, in fact, specifically explores the
perceived ease of use, such as the degree of difficulty that the use
of a technology system involves, and the perceived usefulness,
as the belief that the use of a specific technology system allows
improving one’s own productivity. For the purpose of the present
study, we focus our analysis only on determined domains of the
scale: Perceived usefulness, perceived ease of use, perceptions of
external control, perceived enjoyment, Job relevance. Response
on a 7-point Likert scale were collected (Totally Disagree = 1/
Totally Agree= 7).
Finally, an ad-hoc questionnaire was created with the purpose
to investigate specific barriers patients experienced during
rehabilitation at home. This tool was additionally administered
to patients recruited in Don Gnocchi Foundation for a deepened
investigation. The questionnaire was composed by 11 items
with a 5-point Likert scale (0 = Absolutely not/Never, 4 =
Very much/Always) (see Table S1 to consult the tool). The
questionnaire was scored grouping items into 5 groups in order
to obtain 5 total indexes related to crucial aspects to investigate
barriers encountered during experience of telerehabilitation. In
particular, we analyzed answers extracting the following indexes:
(1) motivation (mean score of item 6 and 8) [Did you need
support of other persons (ex. your son, bride/wife. . . ) to be
motivated to perform HEAD activities (did they remind you to do
them?)/When I didn’t perform activities it was because I wouldn’t],
(2) logistics (mean score of item 1 and 2) [Did having HEAD
system at home bother you?”/“How much did you need to modify
arrangement of furniture to place HEAD technology devices?”], (3)
autonomy (mean score of item 5 and 6) [Did you need support
of other persons (ex. Your son, bride/wife. . . ) to prepare HEAD
technology setting?/Did you need support of other persons (ex. your
son, bride/wife. . . ) to perform HEAD activities?], (4) inclusion in
the routine (mean score of item 3, 4 and 9) [Did you modify your
routine to include HEAD activities during the week (ex. Did you
eat earlier than usual? Did you stop to have nap after lunch?)/Did
you renounce to perform other activities to do HEAD program?/
When I didn’t perform activities it was because I couldn’t], (5)
technical problems (mean score of item 10 and 11) [When I didn’t
perform activities it was because the system did not work/When I
didn’t perform activities it was because even if the system worked,
the internet connection did not].
Patient-Reported Outcome Measures
Two categories of International Classification of functioning [ICF
(39)] on activities and participation in daily life were considered
as PROMs: Carrying out daily routine (d230) and Recreation and
leisure (d920). These categories were extracted by administering
the item 3 of EuroQoL EQ-5D-5L (40–43) and the item 12
of Short Form 12 health survey questionnaire [SF12 (44–47)],
respectively. These two items were then translated in the 5 ICF
qualifiers. Specifically, we associated ICF qualifier 4 (complete
problem) to answer “All the time/Extremely,” qualifier 3 (severe-
complete problem) to answer “Most of the time/a good bit
of the time/Quite bit,” qualifier 2 (moderate-severe problem)
to answer “Some of the time/Moderately,” qualifier 1 (mild-
moderate problem) to answer “A little of the time/a little bit”
and qualifier 0 (no problem) to answer “Never/Not,” following
previous mapping works (44, 46).
Statistical Analysis
Statistical analysis was performed using MedCalc R© Software
Version 15.2.1.
Normal distribution of variables was checked through
Kolmogorov-Smirnov normality test. According to this test,
parametric or non-parametric analysis were performed for
the comparison among three pathology groups (PD vs. MS
vs. stroke).
To analyze efficiency measures such as adherence to
HEAD treatment, usability and acceptance of the HEAD
system, descriptive statistics were run in each pathology
group. Comparison among groups was also reported
through ANCOVA or General Linear Model, by covarying
for recruitment center. Bonferroni post-hoc test was considered.
To analyze ad-hoc questionnaire results we performed
descriptive statistics.
To analyze PROMs, we reported the distribution of qualifiers
(percentages) of the ICF categories at the different time points
(Enrollment T0, post ClinicHEAD T1, and post HomeHEAD
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TABLE 2 | Summary statistics and comparison results of patient groups at baseline.
PD MS Stroke Comparison [Test (p)] All
TIME 1: ClinicHEAD
N 30 32 45 – 107
Age (M ± sd) 66.30 ± 8.77 52.75 ± 10.62 61.04 ± 13.25 11.29 (<0.001) 60.04 ± 12.43
Sex (M:F) 16:14 15:17 26:19 0.89 (0.640) 57:50
Education 11.73 ± 4.40 11.22 ± 3.25 12.44 ± 4.12 0.92 (0.401) 11.88 ± 3.96
MoCA 23.60 ± 3.41 23.69 ± 3.19 21.71 ± 4.79 3.05 (0.051) 22.83 ± 4.08
2MWT 131.66 ± 37.30 92.36 ± 34.11 81.94 ± 43.91 13.72 (<0.001) 100.77 ± 44.44
10MWT 1.41 ± 0.52 0.98 ± 0.52 0.84 ± 0.47 10.55 (<0.001) 1.07 ± 0.55
TIME 2: HomeHEAD
N 11 14 13 – 38
Age (M ± sd) 65.55 ± 9.06 51.93 ± 8.76 57.77 ± 17.17 3.73 (0.034) 57.87 ± 13.25
Sex(M:F) 4:7 7:7 6:7 0.48 (0.112) 17:21
Education 11.27 ± 4.69 12.07 ± 3.25 14.85 ± 4.00 2.79 (0.075) 12.79 ± 4.15
MoCA 22.91 ± 3.21 23.85 ± 3.74 22.62 ± 5.44 0.20 (0.819) 23.13 ± 4.20
2MWT 131.64 ± 38.94 93.96 ± 31.57 79.54 ± 26.22 7.31 (0.003) 101.27 ± 38.36
10MWT 1.43 ± 0.59 1.04 ± 0.47 0.83 ± 0.34 4.48 (0.019) 1.09 ± 0.52
2MWT, 2 minutes walk test; 10MWT, 10 meters walk test; M, mean; MoCA, Montreal Cognitive Assessment; MS, multiple sclerosis; N, number; PD, Parkinson Disease; sd,
standard deviation.
T2). Then, patients were classified into delta score≤ 0, indicating
a perception of maintenance or amelioration over time, and
delta score > 0, referring a perception of worsening over time.
Percentages of sample reporting delta score ≤ 0, reported as
stable/ameliorated patients, and delta score > 0, as worsened
patients, were calculated and Chi-square χ2 was performed.
Results were considered statistically significant when p< 0.05.
RESULTS
Participants
Table 2 shows demographic characteristics of sample included in
the study.
ClinicHEAD: All patients enrolled in the study (n = 107)
followed a program of 12 sessions of HEAD rehabilitation in
clinic. A total of 107 patients with CNDs was composed of 30
people with PD, 32 with MS and 45 with chronic stroke. The
three groups were comparable in terms of gender distribution
(χ2 = 0.89, p = 0.640) and years of education (F = 0.92, p =
0.401) while there was a statistically significant difference in age
between MS and the other two groups (F = 11.29, p < 0.001).
In terms of global cognitive level, we found a trend for a lower
MoCA score in stroke patients compared to those with MS or PD
(F = 3.05, p = 0.051). Finally, endurance and velocity assessed
through 2MWT and 10MWT scores were significantly higher in
PD than in other patients’ groups (2MWT: F = 13.72, p < 0.001;
10MWT: F= 10.55, p< 0.001).
HomeHEAD: Thirty-eight patients were then allocated to
HomeHEAD treatment after ClinicHEAD period to test the
system for the continuity of care at home. In particular, 11
PD, 14MS, 13 stroke were assigned to telerehabilitation at
home. Similarly to the ClinicHEAD sample, patients groups were
comparable for gender distribution (χ2 = 0.479, p = 0.112) and
education (F = 2.79, p = 0.075), but not for age: we reported
a statistically significant difference between PD and MS group
(F = 3.73, p = 0.034). The three groups did not differ in
MoCA score. Instead, endurance assessed through 2MWT was
significant higher in PD than in other patients’ groups (F= 7.31,
p = 0.003) and velocity assessed through 10MWT was major in
PD than stroke (F= 4.48, p= 0.019).
The group enrolled for ClinicHEAD and the sub-group
allocated to HomeHEAD did not significantly differ in gender
distribution (χ2 = 1.42, p = 0.116), age (F = 2.00, p = 0.160),
education (F = 2.33, p = 0.130), global cognitive level (F = 0.15,
p = 0.698), endurance (F = 0.03, p = 0.868), and velocity (F =
0.33, p= 0.569).
Efficiency Measures Results
In Table 3 we report data on efficiency measures after
ClinicHEAD (Time 1) and after HomeHEAD (Time 2), in the
three pathologies.
After ClinicHEAD we found a high level of adherence to
treatment in all three patients’ groups (mean score of all sample:
0.92 ± 0.13) with no significant differences among patients’
groups (F = 1.23, p = 0.296). In terms of duration of treatment,
as number of activities per session and minutes per session,
each session consisted of about 40minutes multidimensional
treatment and was composed of about 4–5 activities. We did
not find differences among groups in number of activities (F
= 0.40, p = 0.675) and minutes of session (F = 0.90, p =
0.408). We registered only 1 drop out. In terms of perceived
usability of the HEAD system in clinic, we reported a good
level of usability, with a median SUS score of 70.00 in all
patients’ groups with no differences among pathologies (F= 0.77,
p = 0.679). Finally, considering sub-domains of TAM3, such
as perceived system Usefulness, Ease of use, External control,
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TABLE 3 | Efficiency measures results of treatment in clinic.
PD MS Stroke Comparison [Test(p)] All
TIME 1: ClinicHEAD
N 30 32 45 – 107
Adherence 0.93 ± 0.11 0.90 ± 0.18 0.94 ± 0.10 1.23(0.296)* 0.92 ± 0.13
Duration of treatment (M ± sd)
Number of activities 4.54 ± 1.70 4.97 ± 1.39 4.16 ± 0.88 0.90(0.408)* 4.51 ± 1.34
Duration of session, min 39.62 ± 18.14 43.70 ± 18.54 36.81 ± 13.05 0.40(0.675)* 39.65 ± 16.42
SUS (Median, 25–75 percentile) 68.75,
60.00–82.50
75.00,
62.50–84.38
70.00,
62.50–80.63
0.77 (0.679)§ 70.00,
62.50–82.50
Usability 2.88,
2.63–3.29
3.14,
2.75–3.43
3.00,
2.63–3.38
1.64 (0.440)§ 3.00,
2.63–3.43
Learnability 3.00,
1.50–3.50
2.50,
1.50–3.50
2.50,
1.50–3.50
0.99 (0.605)§ 2.50,
1.50–3.50
TAM3 (M ± sd)
Usefulness 5.54 ± 1.36 5.08 ± 1.58 5.50 ± 1.31 2.82(0.065)* 5.39 ± 1.41
Ease of use 5.59 ± 0.92 5.53 ± 1.09 5.55 ± 1.12 0.28(0.760)* 5.55 ± 1.05
External control 5.05 ± 0.92 4.93 ± 1.39 4.86 ± 1.15 0.77(0.466)* 4.94 ± 1.17
Relevance 5.84 ± 1.51 5.30 ± 1.40 5.84 ± 0.99 1.37(0.260)* 5.68 ± 1.29
Enjoyment 5.67 ± 1.33 5.91 ± 1.02 5.56 ± 1.66 0.47(0.629)* 5.70 ± 1.40
TIME 2: HomeHEAD
N 11 14 13 – 38
Adherence 0.86 ± 0.14 0.66 ± 0.28 0.82 ± 0.15 6.00(0.007)* 0.77 ± 0.22
Duration of treatment (M ± sd)
Number of activities 3.88 ± 0.90 4.03 ± 0.83 3.24 ± 0.42 0.81 (0.457)* 3.72 ± 0.80
Duration of session, min 37.74 ± 7.61 37.57 ± 9.89 30.66 ± 5.67 0.72 (0.497)* 35.17 ± 8.47
SUS (Median, 25–75 percentile) 85.00,
77.50–92.50
67.50,
55.00–85.00
80.00,
68.13–84.38
3.14 (0.205)* 80.00,
67.50–85.00
Usability 3.36,
3.25–3.71
2.86,
2.42–3.43
3.13,
2.65–3.50
2.46 (0.292)* 3.20,
2.57–3.50
Learnability 4.00,
2.50–4.00
2.50,
1.50–3.63
3.00,
2.63–3.88
3.06 (0.195)* 3.00,
2.00–4.00
TAM3 (M ± sd)
Usefulness 5.25 ± 1.97 5.23 ± 1.11 5.53 ± 0.10 1.47(0.254)* 5.33 ± 1.29
Ease of use 4.68 ± 1.10 5.75 ± 1.21 5.65 ± 1.01 2.18(0.139)* 5.45 ± 1.17
External control 4.89 ± 0.45 4.95 ± 1.27 5.38 ± 0.95 0.50(0.613)* 5.07 ± 1.01
Relevance 5.62 ± 1.50 5.50 ± 1.10 6.04 ± 0.90 0.50(0.616)* 5.70 ± 1.13
Enjoyment 6.00 ± 1.29 5.97 ± 0.10 6.06 ± 1.14 0.97 (0.396)* 6.01 ± 1.08
M, mean; MS, multiple sclerosis; N, number; PD, Parkinson Disease; sd, standard deviation; SUS, System Usability Scale; TAM3, Technology Acceptance Model-3. *ANCOVA
comparison was performed co-varying recruiting center, age, gender, education; §Kruskall-Wallis test was performed.
Relevance and Enjoyment, data of all groups supported the high
level of functionality of HEAD technology (Usefulness: mean
score 5.39 ± 1.41; Ease of Use: mean score 5.55 ± 1.05; External
Control: mean score 4.94 ± 1.17), the perceived treatment
efficacy (Relevance: mean score 5.68 ± 1.29) and the motivating
aspects of HEAD contents (Enjoyment: mean score 5.70± 1.40).
No differences among patients’ groups were registered in all
TAM3 subscores (Usefulness: F = 2.82, p = 0.065; Ease of Use:
F = 0.28, p = 0.760; External control: F = 0.77, p = 0.466;
Relevance: F= 1.37, p= 0.260; Enjoyment: F= 0.47, p= 0.629).
At HomeHEAD (Time 2), we registered 7.89% of drops in
the whole group. In general, we reported a discrete adherence
to treatment at home (mean score in whole group: 0.77 ± 0.22).
More specifically, we observed a better adherence to treatment
in PD and stroke groups than in the MS group (F = 6.00, p =
0.007). Focusing on duration of treatment, we did not find group
differences in the number of activities performed per session (F
= 0.81, p = 0.457) nor in the length of treatment per session (F
= 0.72, p= 0.497).
Patient assessment of system usability, as shown by SUS score,
was higher in the PD group (median: 85.00) compared to stroke
(median: 80.00) and MS (median: 67.50) groups. In general,
usability of the system at home was estimated as good (median
of whole group: 80.00). No differences among pathologies groups
were reported (F= 3.14, p= 0.205).
Results of TAM3 questionnaire highlighted high level of
functionality of the system at home in all domains explored
(Usefulness: 5.33 ± 1.29; Ease of Use: 5.45 ± 1.17; External
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Control: 5.07 ± 1.01; Relevance: 5.70 ± 1.13; Enjoyment: 6.01
± 1.08), suggesting that patients perceived HEAD program as
useful, easy to use, intuitive, relevant for everyday life and
playful. Again, patients’ groups did not differ in TAM3 subscores
(Usefulness: F= 1.47, p= 0.254; Ease of Use: F= 2.18, p= 0.139;
External Control: F = 0.50, p = 0.613; Relevance: F = 0.50, p =
0.616; Enjoyment: F= 0.97, p= 0.396).
Additionally, adherence to single sessions at home for all
period of telerehabilitation (60 sessions, 5 sessions/week) was
observed. In particular, we analyzed adherence to sessions in each
single week of treatment in each pathology group, considering
percentage of adherence to session in each week (1 = adherence
to 5 sessions/week; 0= adherence to 0 sessions/week).
Table 4 reports percentage of adherence to sessions in each
week (1 = adherence to 5 sessions/week; 0 = adherence to 0
sessions/week) and the mean number of activities per session in
each of 12 weeks of treatment at home.
Based on recent data on recommended frequency of treatment
to guarantee rehabilitation effectiveness (19), we considered
0.60 as the ideal adherence per week (3 sessions/5 per week
= 1.00). We reported a good adherence (more than 88%)
of PD group from the second to the eleventh week of
treatment. Stroke group showed an adherence > 80% from the
first to the eighth week of treatment, followed by a discrete
adherence (75%) in the ninth and tenth week. MS group,
instead, demonstrated a discontinuous adherence to treatment,
by reported an adherence>85% only from second to forth week.
Overall, the whole group presented a good adherence (>82%)
from the second to the eighth week of treatment (for details,
see Table S2).
Ad-hoc questionnaire on barriers possibly experienced at
home reported positive data.
People reported to have encountered very few barriers
during their experience of HEAD telerehabilitaiton. In particular,
all participants were motivated to carry out rehabilitation
as mean score of motivation barriers was 0.03 ± 0.13.
Also, from a logistical point of view, the presence of the
technological kit in one’s home was not perceived as burdensome,
as suggested by the low mean score of logistical barriers:
0.31 ± 0.36. Another positive result was that people could
perform activities in autonomy: although sometimes preparation
of technological setting needed help from the caregiver,
performing activities did not. In fact, we collected a mean
score of autonomy barriers of 0.31 ± 0.44. Furthermore,
HEAD rehabilitation resulted well-integrated into patients’
routine: we reported a mean score of 0.40 ± 0.30 at
inclusion in the routine barriers. Finally, technological problems
represented the only barrier that sometimes impeded the
performance of activities: mean score of technological issues was
0.94± 0.73.
Patient-Reported Outcome Measures
Results
The whole sample was classified as moderate-to-severe in
autonomy in daily routine (d230 ICF domain) and as mild-to-
moderate in socialization (d920 ICF domain) at baseline.
We report in Table 5 percentages of patients who perceived
HEAD treatment as successful in their daily living (daily routine
and socialization) and who did not, by reporting a change of level
of autonomy and socialization in daily life between baseline and
after HEAD treatment in all group that experienced ClinicHEAD
(Time 1) (n = 107) and in the sub-group who additionally
experienced HomeHEAD (Time 2) (n = 38). We considered
as stable or ameliorated patients who presented an ICF score
change between time points = 0 or ≤ 1, such as a perceived
successful effect of HEAD treatment. On the contrary, patients
were considered as worsened when they reported an ICF score
change ≥ 1.
We did not find differences for T1-baseline measures between
ClinicHEAD and HomeHEAD group (d230: p = 0.476; d920:
p= 0.278).
ClinicHEAD: Results showed a high percentage of people
with PD (97%) who reported a perceived maintenance or
amelioration of functioning in daily life after 12 sessions of
HEAD treatment in clinic. Also, a high percentage of patients
with stroke judged a positive influence of HEAD treatment
on participation in daily living (82%) and a discrete part of
the group extended this perception to performance in daily
routine (74%). We didn’t find similar results in MS group,
in which only 59% of patients perceived a successful effect of
treatment. In general, a significantly higher number of people
who perceived treatment as successful on daily life functioning
was registered than people who did not (p < 0.001). This latter
result appeared evident in PD and stroke groups, but not in the
MS group.
HomeHEAD: We observed satisfying results in the PD group
after experience at home. In fact, the entire group (100%) judged
a successful effect of HEAD on daily routine and 80% of the
sample referred to same perception in daily participation after
telerehabilitation. Also the stroke group, which showed positive
reported outcome after ClinicHEAD rehabilitation, indicated
positive results after rehabilitation at home, with 82% of patients
registering a positive effect of telerehabilitation on daily routine
and 73% reporting benefits also on participation. Interestingly,
the MS group, reported positive results in more than 80%
of the group in both daily routine and participation after
telerehabilitation at home. In general, we found a significant
number of patients reporting positive effect of HEAD treatment
on daily functioning (d230: p< 0.001; d920: p= 0.003).
DISCUSSION
We tested efficiency of HEAD, a new technology enabled
rehabilitation program for the continuity of care at home for
people with CNDs, such as PD, MS, and chronic stroke based
on key performance indicators. In particular, we explored HEAD
usability and acceptability together with patient’s adherence to
treatment, and PROMs, as perceived functioning in routine and
participation in daily life. We observed output and outcome
measures in clinic for a training duration of 1-month (12
sessions) and in continuity of care at home for a total duration
of 3-months (60 sessions).
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TABLE 4 | Total adherence to HEAD telerehabilitation along 3-months of treatment at home.
W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 W12
Adherence %
PD 0.64 0.80 0.87 0.96 0.93 0.93 0.93 0.89 0.84 0.78 0.80 0.67
MS 0.66 0.79 0.88 0.83 0.68 0.67 0.71 0.69 0.65 0.57 0.55 0.43
Stroke 0.80 0.92 0.92 0.92 0.90 0.87 0.88 0.79 0.74 0.77 0.62 0.57
Whole group 0.71 0.84 0.89 0.89 0.82 0.81 0.83 0.78 0.74 0.69 0.64 0.55
Activities/session
PD 3.73 4.14 3.64 4.09 3.55 3.95 4.02 3.98 4.03 4.51 4.47 4.23
MS 4.12 4.26 4.04 4.15 4.05 4.20 4.24 4.27 4.18 4.35 4.27 4.58
Stroke 3.52 3.58 3.60 3.35 3.26 3.35 3.25 3.20 3.13 3.00 2.65 2.94
Whole group 3.78 3.97 3.77 3.84 3.59 3.79 3.80 3.80 3.74 3.87 3.77 3.85
MS, multiple sclerosis; PD, Parkinson Disease; W, week; %, percentage. Adherence > 80% is reported in bold.
Our results highlighted a very high compliance rate in
all three patient groups in clinic, with 92% adherence to
treatment. This data is extremely relevant given that Evidence-
Based Medicine guidelines reported 80% as minimum rate of
adherence needed to appraise quality of clinical trials (42). In
particular, we found that stroke patients followed on average
94% of sessions, whereas the numbers were 93 and 90% for
PD and MS, respectively. This positive data can be explained
by two main factors. First, the ease of use of the technological
system can have affected participation to treatment. In fact,
from the point of view of usability, our patients judged the
system in clinic as efficient. This is particularly important, since
the potential effect of DH is strictly related to the perceived
ease of use of health care systems (43, 46). Also, investigating
perceived acceptability together with usability of the system
we reported satisfying feedbacks regarding HEAD technology
acceptance in all three pathologies. Especially, facility of use,
usefulness of the program, a good control of the system,
perception of relevance on their everyday life and enjoyment was
observed. Second, the modality of implementation of activities
can have influenced motivation to treatment. Especially, HEAD
activities were presented in a VR setting and recent evidence
has supported the role of VR in influencing outcome by
adhering to basic principles of rehabilitation such as intensity,
environment, bio-feedback and motivation (47). Moreover, each
activity was embedded in a multimedia content, consisting
of short video clips, thought to be motivating for patients.
Video clips have historically been used to elicit emotion and
motivate people, and their dynamic nature appears to be useful in
eliciting interest as well as providing an optimal artificial model
of reality (48–50).
Having demonstrated the efficiency of the HEAD program
in clinic, we focused also on efficiency of the system during
telerehabilitation at home for 3-months. Usability and acceptance
of HEAD system at home was high in the whole sample,
suggesting a good functionality of the system in telerehabilitation.
The high score of sub-domain “Enjoyment” of TAM-3 supported
the motivating feature of the rehabilitation activities, probably
due to variability of the contents included in activities during
3-months of rehabilitation. Moreover, the game-setting of
the rehabilitative activities probably played a crucial role in
enjoyment and consequently in acceptance of DH-treatment.
Accordingly, a recent study demonstrated that game elements
affect duration of enjoyment during motor exercises (51). Also,
focusing on adherence, <8% of patients did not complete
the entire treatment program. This is an important result
since continuity of care is crucial in order to do not lose
functional recovery after discharge to home (52, 53). However,
while the mean adherence to treatment was over 80% in
all 3 patients’ groups in the first 2-months, it was lower in
the last month of the program. This may be due to the
high intensity of the home program: the HEAD program was
administered 5 sessions/week for 3-months while Kim’s et al.
(19) work indicated a maximum of 2–3 sessions per week in
the MS population. When considering 3 sessions/week as ideal
adherence over time, we found a globally longer persistence
over telerehabilitation weeks, with, for example, high adherence
over 11 weeks/12 in PD group. Moreover, we observed different
patterns of adherence in distinct pathologies: with a better
adherence in PD and stroke than in MS. This lower adherence
to treatment of the MS group might be due to the fatigue
that this population experiences during treatment and in daily
life (54). It is known that MS patients are faced with elevated
challenges when following long-term intervention and there
is an urgent need of future research focusing on solutions
for continuity of care and exercise persistence in the MS
population (55, 56). Moreover, we considered the implication
of the video contents included in HEAD activities: movie clips
were collected from historically famous movies of years 1940–
1990 (obtained by RAI, Italian Radio Television s.p.a.) with
the purpose to stimulate positive memories of patients and as
such they may have been more targeted to an older audience.
The younger age of the MS group compared to the other
two pathologies may have contributed to the perception of
these contents as not engaging enough. This result stresses
the importance of tailoring contents of rehabilitation to age of
population targeted, further studies are needed to better elucidate
this issue.
A DH approach is not without barriers. Moving the
rehabilitation context outside the clinic can result in difficulties
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TABLE 5 | Changes in autonomy (d230) and participation (d920) after ClinicHEAD and after HomeHEAD.
ICF
category
T ICF qualifier (%) T1 vs. T0 T2 vs. T0*
No
problem
Mild
problem
Moderate
problem
Severe
problem
Complete
problem
Stabilization
/amelioration %
Worsening
%
p Stabilization
/amelioration %
Worsening
%
p
PD d230 0 23.3 20.0 40.0 16.7 0.0 0.97 0.03 <0.001 1.00 0.00 –
1 33.3 30.0 26.7 10.0 0.0
2* 36.4 45.5 9.1 9.0 0.0
d920 0 33.3 16.7 33.3 16.7 0.0 0.83 0.17 <0.001 0.80 0.20 0.114
1 37.9 20.7 27.6 13.8 0.0
2* 36.4 18.2 27.3 18.1 0.0
MS d230 0 22.6 19.4 35.5 19.4 3.1 0.59 0.41 0.441 0.89 0.11 0.045
1 13.9 17.2 44.8 17.2 6.9
2* 25.0 41.7 33.3 0.0 0.0
d920 0 30.0 26.7 20.0 20.0 3.3 0.63 0.37 0.359 0.82 0.18 0.070
1 24.2 17.2 37.9 20.7 0.0
2* 33.3 33.3 16.7 16.7 0.0
STROKE d230 0 11.1 37.8 26.7 17.8 6.6 0.74 0.26 0.002 0.82 0.18 0.070
1 18.3 29.5 29.5 18.2 4.5
2* 16.7 33.3 33.3 16.7 0.0
d920 0 31.8 20.5 22.7 22.7 2.3 0.82 0.18 <0.001 0.73 0.27 0.228
1 35.6 15.6 26.7 15.6 6.5
2* 33.4 8.3 33.3 25.0 0.0
ALL d230 0 17.9 27.4 33.0 17.9 3.8 0.77 0.23 <0.001 0.90 0.10 <0.001
1 21.4 26.2 33.0 15.5 3.9
2* 25.7 40.0 25.7 8.6 0.0
d920 0 31.7 21.2 25.0 20.2 1.9 0.79 0.21 <0.001 0.78 0.22 0.003
1 33.0 17.5 30.1 16.5 2.9
2* 34.3 20.0 25.7 20.0 0.0
d230, Carrying out daily routine; d920, Recreation and participation; ICF, International Classification of Functioning; MS, Multiple Sclerosis; PD, Parkinson Disease. *, HomeHEAD group
(n = 38); %, percentage. ps < 0.05 are reported in bold.
for patients to manage technology systems on their own
and include treatment in their daily routine. We evaluated
the frequency of patients’ experience of the most common
barriers during 3-months of tele-treatment. Patient feedback
suggested that all participants were highly motivated, that
they included HEAD program in their routine, did not
encounter logistical problems and were able to conduct
rehabilitation activities in autonomy. The overall positive
judgments support the suitability of DH in a context of
global transition of CNDs rehabilitation treatment from inside
to outside the clinic (57). The only barriers encountered
were technology problems, probably due to the innovative
features of the technology system. This is likely an obstacle
that will be solved in the near future since technology
transformation over time will lead to increasingly more tailored
and useable systems.
Moving from efficiency to focus on PROMs enabled us
to deepen our understanding of patient perceptions regarding
effectiveness of treatment on their functioning in everyday life.
Recent works recommended the application of these measures
as extremely informative (27), especially in the investigation
of effects of newly implemented DH treatments that often are
conducted in a home-based context. In the present study a
consistent number of subjects referenced a positive effect of
treatment particularly on performance of activities in daily
life (90%) and socialization (78%). Interestingly, we found a
maintenance or amelioration of functioning in daily living
especially high after treatment at home, with a greater number
of patients reporting positive effect on autonomy in their routine
after telerehabilitation at home vs. rehabilitation treatment in
clinic (90% of subjects vs. 78%). This evidence is crucial,
in accordance with suggestion of Steinhubl et al. (58), who,
reporting definitions and scenarios fostered by the new mobile
health technologies, declare that changes in the care environment
are able to provide better outcomes. More importantly, this
result is in line with the main goal of rehabilitation itself,
that aims at the recovery of the patient’s functioning in terms
of its utilization in daily living; all in the overall context of
the biopsychosocial digital model that foresees a collaboration
between clinicians and patient facilitated by DH in the social
context of the person (9). Considering socialization in daily life,
we found different outcome in the three pathologies. There was
a better perception of socialization after the in-clinic HEAD
program than following the home telerehabilitation program. On
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the contrary, MS patients showed an increase in socialization
after telerehabilitation at home compared to the clinic. This
result may be related to the phenomenon of the baby boomer
generation: people born between 1946 and 1964 need to be
introduced to technology. Instead, younger people, nearer to
millennials, are more familiar with technology systems. Hence,
our results could be explained by demographic factors of our
population targets: patients with an older age, such as those
with PD and stroke, appreciated HEAD potential benefit on
socialization more in clinic setting than at home, while younger
people, such as the MS sample in our study, are able to report
treatment potentiality on their daily life when it is fostered in
their home setting.
Targeting three pathologies, MS, PD, and Stroke in this
study leads to smaller sample size for each group which could
constitute a limitation. However, one of the hallmarks of the
proposed study is its adaptability to different functional levels
and its suitability for different neurological disorders. In fact,
one of the problems other studies have faced in the past is
the narrow applicability of their intervention systems (59). The
HEAD protocol is developed to overcome this problem. This
study proposes to investigate the responsiveness of the tested
intervention to the needs of diverse populations with chronic
neurological pathologies that are typically seen in rehabilitative
practices and need to have access to monitored continuity of
rehabilitative activities.
While the sample size of this study is too small to draw
conclusive evidence of the efficacy of the proposed intervention,
the results support HEAD as a useful and acceptable DH-care
system for people with CNDs with positive impacts on the
perceived benefits for autonomy and daily life involvement. This
is important given the crucial role technology will play in future
neurorehabilitation models. Our findings support the notion that
intensity and duration of long-term interventionmust be tailored
to the individual, taking into account also the personalization
of contents to maintain an adequate level of engagement in
rehabilitation at home.
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